

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/009,476	12/11/2001	Toshio Kasama	2260/50666	1854	
75	90 05/20/2003				
Crowell Moring			EXAMINER		
1001 Pennsylvania Avenue NW Washington, DC 20004-2595			AZPURU, CARLOS A		
			ART UNIT	PAPER NUMBER	
			1615		
			DATE MAILED: 05/20/2003	r	
				Þ	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.		Applicant(s)			
Office Action Summary		10/009,476		KASAMA ET AL.			
		Examiner		Art Unit			
		Carlos A. Azpuru		1615			
The MAILING DATE of this communication appears on the cov r she t with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1) 🗆	Responsive to communication(s) filed on	·					
2a)□) ☐ This action is FINAL . 2b) ☑ This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4) Claim(s) 1-11 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5)⊠ Claim(s) <u>1-7,10 and 11</u> is/are allowed.							
6)⊠ Claim(s) <u>8 and 9</u> is/are rejected.							
7) Claim(s) is/are objected to.							
· ·	Claim(s) are subject to restriction and/o	r election requireme	ent.				
Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)⊠ All b)□ Some * c)□ None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice 2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) 3	5) 🔲 No		(PTO-413) Paper No atent Application (PT			
J.S. Patent and Tra PTO-326 (Rev		tion Summary		Part of Paper No. 6			

DETAILED ACTION

Receipt is acknowledged of the information disclosure statement and preliminary amendment filed 12/11/01.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 8 and 9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 8 is indefinite in its Markush Grouping of further constituents of the claimed ophthalmic ointment. In particular, white petrolatum appears to be equivalent to gelation hydrocarbon, Macrogol would appear to be a hydrophilic ointment base, and the distinction between white hydrophilic ointment base, ointment base, ointment base, and simple ointment base is unclear. Additionally, the generic name of Macrogol should appear in parentheses next to the tradename. Because the distinction between members of the Markush Group can not be made, the metes and bounds of the Markush Grouping are indefinite.

Claim 9 is similarly indefinite in that several of the class of compounds listed after the pharmaceutical excipients classified as antiseptics, surfactants, and stabilizers appear to overlap with this type of excipient. For example, glycerol maty be a stabilizer,

Application/Control Number: 10/009,476

Art Unit: 1615

and isopropyl myristate can be used as a surfactant. As above, the metes and bounds of the Markush Grouping are indefinite.

Clarification is requested for both of these claims.

Hanna (Delivery of Antibiotics to the Eye) is cited for its disclosure of the prior art attempts at delivery antibiotics to the eye.

Claims 1-7, 10, and 11 are allowed. Correction and clarification of claims 8 and 9 would place the application in condition for allowance.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carlos A. Azpuru whose telephone number is 703/308-0237. The examiner can normally be reached on Tu-Fri, 6:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Art Unit: 1615

ca May 16, 2003

> ARLOS AZPURU PRIMARY EXAMINER